Whitehawk Therapeutics WHWK 深 沪
交易中 10-12 11:58:50 美东时间
3.47
-0.050
-1.42%
华盛通- 最 高3.56
- 今 开3.52
- 成交量 2.60万股
- 最 低 3.44
- 昨 收 3.52
- 总市值 19.78万
- 52周最高 5.495
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 1.97
- 委 比 -52.02%
- 总股本 5.70万
- 历史最高 65.25
- 量 比 0.22
- 振 幅 3.41%
- 历史最低 1.21
- 每 手 1
- 风险率 0.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175...
10-07 19:03
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9
Stifel analyst Dara Azar initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy rating and announces Price Target of $9.
10-01 19:03
Whitehawk Therapeutics Adds Oncology Leader to Board
The latest update is out from Whitehawk Therapeutics ( ($WHWK) ). On September ...
09-11 05:29
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Expanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome modulating payload platform in combination with Whitehawk's topoisomerase I payload platform. The collabor...
08-14 04:45
Whitehawk Therapeutics Q2 EPS $(0.20) Beats $(0.30) Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 73.68 percent increase over losses of $(0.76) per share from the same period last year.
08-06 20:46
Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying adva...
07-21 19:15
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics and Whitehawk Therapeutics have entered into a strategic research collaboration to evaluate Akari's PH1 spliceosome-modulating payload technology in combination with Whitehawk's TOP1i ADC platform. The collaboration aims to explore dual payload compatibility and synergies, with Akari leading the research activities. Both companies will review interim data and assess potential broader development opportunities. This partnership ...
07-21 11:05
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9
Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Outperform rating and announces Price Target of $9.
07-14 01:55
